Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sander W Tas

Showing results (1-10 of 141) with videos related to

Pageof 15
Sort By:
Rheumatology (Oxford, England)|March 25, 2017
How to monitor safety and efficacy of biologic treatment in rare, therapy-refractory immune-mediated inflammatory diseases?Anne Musters, Sander W Tas
Nature Reviews. Rheumatology|January 31, 2020
Room for improvement in clinical trials for rare diseasesAnne Musters, Sander W Tas
Best Practice & Research. Clinical Rheumatology|December 8, 2014
Inhibitors of angiogenesis: ready for prime time?Chrissta X Maracle, Sander W Tas
Methods in Molecular Biology (Clifton, N.J.)|November 5, 2015
Recent Advances in the Treatment of Immune-Mediated Inflammatory DiseasesSander W Tas, Dominique L P Baeten
International Journal of Molecular Sciences|August 12, 2022
Editorial for Special Issue "Advances in the Pathogenesis and Treatment of Immune-Mediated Inflammatory Diseases"Jan Piet van Hamburg, Sander W Tas
Journal of Autoimmunity|December 20, 2017
Molecular mechanisms underpinning T helper 17 cell heterogeneity and functions in rheumatoid arthritisJan Piet van Hamburg, Sander W Tas
Arthritis Research & Therapy|March 17, 2015
Non-canonical NF-κB signaling in rheumatoid arthritis: Dr Jekyll and Mr Hyde?Ae R Noort, Paul P Tak, Sander W Tas
Frontiers in Immunology|August 11, 2023
Editorial: Non-canonical NF-κB signaling in immune-mediated inflammatory diseases and malignanciesSander W Tas, Vanessa L Bryant, Matthew C Cook
International Journal of Molecular Sciences|January 11, 2022
B Lineage Cells in ANCA-Associated VasculitisAna Merino-Vico, Jan Piet van Hamburg, Sander W Tas
Annals of the Rheumatic Diseases|August 14, 2021
Correspondence on "Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: results from the COVID-19 global rheumatology alliance physician registry"Ronald F van Vollenhoven, Sander W Tas, Michael T Nurmohamed
Pageof 15

Showing results (1-10 of 141) with videos related to

Sort By:
Pageof 15
Rheumatology (Oxford, England)|March 25, 2017
How to monitor safety and efficacy of biologic treatment in rare, therapy-refractory immune-mediated inflammatory diseases?Anne Musters, Sander W Tas
Nature Reviews. Rheumatology|January 31, 2020
Room for improvement in clinical trials for rare diseasesAnne Musters, Sander W Tas
Best Practice & Research. Clinical Rheumatology|December 8, 2014
Inhibitors of angiogenesis: ready for prime time?Chrissta X Maracle, Sander W Tas
Methods in Molecular Biology (Clifton, N.J.)|November 5, 2015
Recent Advances in the Treatment of Immune-Mediated Inflammatory DiseasesSander W Tas, Dominique L P Baeten
International Journal of Molecular Sciences|August 12, 2022
Editorial for Special Issue "Advances in the Pathogenesis and Treatment of Immune-Mediated Inflammatory Diseases"Jan Piet van Hamburg, Sander W Tas
Journal of Autoimmunity|December 20, 2017
Molecular mechanisms underpinning T helper 17 cell heterogeneity and functions in rheumatoid arthritisJan Piet van Hamburg, Sander W Tas
Arthritis Research & Therapy|March 17, 2015
Non-canonical NF-κB signaling in rheumatoid arthritis: Dr Jekyll and Mr Hyde?Ae R Noort, Paul P Tak, Sander W Tas
Frontiers in Immunology|August 11, 2023
Editorial: Non-canonical NF-κB signaling in immune-mediated inflammatory diseases and malignanciesSander W Tas, Vanessa L Bryant, Matthew C Cook
International Journal of Molecular Sciences|January 11, 2022
B Lineage Cells in ANCA-Associated VasculitisAna Merino-Vico, Jan Piet van Hamburg, Sander W Tas
Annals of the Rheumatic Diseases|August 14, 2021
Correspondence on "Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: results from the COVID-19 global rheumatology alliance physician registry"Ronald F van Vollenhoven, Sander W Tas, Michael T Nurmohamed
Pageof 15